(Q83131324)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16605284%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

title

A cost-utility analysis of losartan versus atenolol in the treatment of hypertension with left ventricular hypertrophy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16605284%20AND%20SRC:MED&resulttype=core&format=json

left ventricular hypertrophy

19 January 2020

main subject

1 reference

1 reference

5

Bohdan Nosyk

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16605284%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

author name string

Aslam H Anis

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16605284%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Huiying Sun

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16605284%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Sonia Singh

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16605284%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

John Woolcott

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16605284%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Marc Brisson

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16605284%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

publication date

1 January 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16605284%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16605284%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

volume

24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16605284%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16605284%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

page(s)

387-400

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16605284%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.2165/00019053-200624040-00008

19 January 2020

exact match

0 references

cites work

Predictors of resource use after acute hospitalization: the Northern Manhattan Stroke Study

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200624040-00008

Stroke after thrombolysis. Mortality and functional outcomes in the GUSTO-I trial. Global Use of Strategies to Open Occluded Coronary Arteries.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200624040-00008

A prospective community-based study of stroke in Germany--the Erlangen Stroke Project (ESPro): incidence and case fatality at 1, 3, and 12 months.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200624040-00008

A randomised controlled comparison of alternative strategies in stroke care

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200624040-00008

A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension

21 January 2018

1 reference

12 December 2020

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

1 reference

12 December 2020

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

1 reference

12 December 2020

Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan in mild-to-moderate hypertension. Irbesartan/Losartan Study Investigators

1 reference

12 December 2020

The cost-effectiveness of ramipril in the treatment of patients at high risk of cardiovascular events: a Swedish sub-study to the HOPE study.

1 reference

12 December 2020

Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial

1 reference

12 December 2020

Costs of stroke and stroke services: Determinants of patient costs and a comparison of costs of regular care and care organised in stroke services

1 reference

12 December 2020

Evidence-Based Health Policy---Lessons from the Global Burden of Disease Study

1 reference

12 December 2020

The antihypertensive effect and tolerability of candesartan cilexetil, a new generation angiotensin II antagonist, in comparison with losartan

1 reference

12 December 2020

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

1 reference

12 December 2020

Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Research Group

1 reference

12 December 2020

The cost effectiveness of ACE inhibitors as first-line antihypertensive therapy

1 reference

12 December 2020

Awareness, treatment, and control of hypertension in Canada

1 reference

12 December 2020

Cost-Utility analysis of tissue plasminogen activator therapy for acute ischaemic stroke: a Canadian healthcare perspective

1 reference

12 December 2020

Losartan for cardiovascular disease in patients with and without diabetes in the LIFE study

1 reference

12 December 2020

The quality of life of patients with hypertension

1 reference

12 December 2020

Development and validation of the Ontario acute myocardial infarction mortality prediction rules

1 reference

12 December 2020

Economic evaluation of pharmaceuticals. Frankenstein's monster or vampire of trials?

1 reference

12 December 2020

Thinking outside the box: recent advances in the analysis and presentation of uncertainty in cost-effectiveness studies

1 reference

12 December 2020

Atenolol in hypertension: is it a wise choice?

1 reference

12 December 2020

Effects of stroke on medical resource use and costs in acute myocardial infarction. GUSTO I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries Study

1 reference

12 December 2020

Markov models in medical decision making: a practical guide.

1 reference

12 December 2020

Hospital utilization and costs in a cohort of injection drug users

1 reference

12 December 2020

Comparison of baseline data, initial course, and management: losartan versus captopril following acute myocardial infarction (The OPTIMAAL Trial). OPTIMAAL Trial Steering Committee and Investigators. Optimal Trial in Myocardial Infarction with the A

1 reference

12 December 2020

Atrial fibrillation and stroke : concepts and controversies

1 reference

12 December 2020

Primer on Medical Decision Analysis: Part 5—Working with Markov Processes

1 reference

12 December 2020

How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations

1 reference

12 December 2020

Cost-effectiveness of early irbesartan treatment versus control (standard antihypertensive medications excluding ACE inhibitors, other angiotensin-2 receptor antagonists, and dihydropyridine calcium channel blockers) or late irbesartan treatment in

1 reference

12 December 2020

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

1 reference

12 December 2020

Guidelines for the early management of patients with ischemic stroke: A scientific statement from the Stroke Council of the American Stroke Association

1 reference

12 December 2020

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

1 reference

12 December 2020

Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack

1 reference

12 December 2020

The Markov process in medical prognosis.

1 reference

12 December 2020

The cost-effectiveness of the switch towards more expensive antihypertensive drugs.

1 reference

12 December 2020

Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration

1 reference

12 December 2020

A meta-analysis of quality-of-life estimates for stroke

1 reference

12 December 2020

A comparison of the angiotensin II antagonists valsartan and losartan in the treatment of essential hypertension

1 reference

12 December 2020

Primary Prevention of Ischemic Stroke

1 reference

12 December 2020

Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study

1 reference

12 December 2020

ABPM comparison of the antihypertensive profiles of the selective angiotensin II receptor antagonists telmisartan and losartan in patients with mild-to-moderate hypertension

1 reference

12 December 2020